The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SAVA | -91.08% | -60.85% | -17.08% | -97% |
| S&P | +11% | +85.61% | +13.15% | +337% |
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.20M | 23.1% |
| Market Cap | $140.58M | -90.0% |
| Market Cap / Employee | $4.69M | 0.0% |
| Employees | 30 | 3.4% |
| Net Income | -$10.81M | 61.3% |
| EBITDA | -$11.66M | 62.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $106.08M | -43.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.99% | -51.1% |
| Return On Invested Capital | -28.11% | 0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.30M | 65.6% |
| Operating Free Cash Flow | -$6.22M | 66.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.68 | 0.50 | 0.69 | 1.60 | -81.14% |
| Price to Tangible Book Value | 0.68 | 0.50 | 0.69 | 1.60 | -81.15% |
| Enterprise Value to EBITDA | 0.52 | 1.84 | 0.55 | -2.96 | -92.39% |
| Return on Equity | -17.2% | -70.6% | -88.9% | -85.4% | 678.13% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
